Myriad Genetics (MYGN) Beat But Not By Enough, Mizuho Says; PT to $34
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Leerink Partners Remains Sidelined on Myriad Genetics (MYGN) - PT to $41
May 4, 2016 7:44 AM EDTLeerink Partners maintained a Market Perform rating on Myriad Genetics (NASDAQ: MYGN), and cut the price target to $41.00 (from $44.00), following the company's 3Q earnings report. MYGN reported revenue of $190.5M, beating expectations of $185M by ~3%. Management guided F4Q revenue in the... More
Myriad Genetics (MYGN) Tops Q3 EPS by 3c, Offers Q4 & FY Guidance
May 3, 2016 4:07 PM EDTMyriad Genetics (NASDAQ: MYGN) reported Q3 EPS of $0.41, $0.03 better than the analyst estimate of $0.38. Revenue for the quarter came in at $190.5 million versus the consensus estimate of $184.92 million.
GUIDANCE:
Myriad Genetics sees Q4 2016 EPS of $0.36-$0.38, versus the consensus of... More
